These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 8614567

  • 1. Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson's disease.
    Hao R, Ebadi M, Pfeiffer RF.
    Neurosci Lett; 1995 Nov 17; 200(2):77-80. PubMed ID: 8614567
    [Abstract] [Full Text] [Related]

  • 2. The multiple actions of selegiline.
    Ebadi M, Sharma S, Shavali S, Sangchot P, Brekke L.
    Proc West Pharmacol Soc; 2002 Nov 17; 45():39-41. PubMed ID: 12434521
    [No Abstract] [Full Text] [Related]

  • 3. Neuroprotective actions of selegiline.
    Ebadi M, Sharma S, Shavali S, El Refaey H.
    J Neurosci Res; 2002 Feb 01; 67(3):285-9. PubMed ID: 11813232
    [Abstract] [Full Text] [Related]

  • 4. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
    Chiu WH, Carlsson T, Depboylu C, Höglinger GU, Oertel WH, Ries V.
    Neuropharmacology; 2014 Apr 01; 79():212-21. PubMed ID: 24291466
    [Abstract] [Full Text] [Related]

  • 5. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro.
    Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW.
    J Neurochem; 1997 Jan 01; 68(1):33-9. PubMed ID: 8978707
    [Abstract] [Full Text] [Related]

  • 6. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MB, Riederer P, Gerlach M, Oertel WH.
    J Neural Transm (Vienna); 2001 Jan 01; 108(8-9):985-1009. PubMed ID: 11716151
    [Abstract] [Full Text] [Related]

  • 7. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro.
    Mytilineou C, Radcliffe PM, Olanow CW.
    J Neurochem; 1997 Jan 01; 68(1):434-6. PubMed ID: 8978757
    [Abstract] [Full Text] [Related]

  • 8. L-deprenyl (selegiline) limits the repetitive firing of action potentials in rat hippocampal CA1 neurons via a dopaminergic mechanism.
    Huang CC, Tsai JJ, Hsu KS.
    Brain Res; 1997 Apr 04; 753(1):27-35. PubMed ID: 9125428
    [Abstract] [Full Text] [Related]

  • 9. Trophic effects of selegiline on cultured dopaminergic neurons.
    Kontkanen O, Castrén E.
    Brain Res; 1999 May 22; 829(1-2):190-2. PubMed ID: 10350547
    [Abstract] [Full Text] [Related]

  • 10. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ, Swope DM, Dashtipour K.
    Clin Ther; 2007 Sep 22; 29(9):1825-49. PubMed ID: 18035186
    [Abstract] [Full Text] [Related]

  • 11. The neuroprotective and neuronal rescue effects of (-)-deprenyl.
    Magyar K, Szende B, Lengyel J, Tarczali J, Szatmáry I.
    J Neural Transm Suppl; 1998 Sep 22; 52():109-23. PubMed ID: 9564614
    [Abstract] [Full Text] [Related]

  • 12. Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.
    Liu Z, Cai W, Lang M, Yan R, Li Z, Zhang G, Yu P, Wang Y, Sun Y, Zhang Z.
    J Mol Neurosci; 2017 Apr 22; 61(4):498-510. PubMed ID: 28144826
    [Abstract] [Full Text] [Related]

  • 13. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.
    Finberg JP, Takeshima T, Johnston JM, Commissiong JW.
    Neuroreport; 1998 Mar 09; 9(4):703-7. PubMed ID: 9559942
    [Abstract] [Full Text] [Related]

  • 14. L-deprenyl fails to protect mesencephalic dopamine neurons and PC12 cells from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.
    Vaglini F, Pardini C, Cavalletti M, Maggio R, Corsini GU.
    Brain Res; 1996 Nov 25; 741(1-2):68-74. PubMed ID: 9001706
    [Abstract] [Full Text] [Related]

  • 15. Cerebrospinal fluid of Parkinson's disease patients inhibits the growth and function of dopaminergic neurons in culture.
    Hao R, Norgren RB, Lau YS, Pfeiffer RF.
    Neurology; 1995 Jan 25; 45(1):138-42. PubMed ID: 7824104
    [Abstract] [Full Text] [Related]

  • 16. Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
    Mercuri NB, Scarponi M, Federici M, Bonci A, Siniscalchi A, Bernardi G.
    Ann Neurol; 1998 May 25; 43(5):613-7. PubMed ID: 9585355
    [Abstract] [Full Text] [Related]

  • 17. Neuroprotection of MAO-B inhibitor and dopamine agonist in Parkinson disease.
    Kong P, Zhang B, Lei P, Kong X, Zhang S, Li D, Zhang Y.
    Int J Clin Exp Med; 2015 May 25; 8(1):431-9. PubMed ID: 25785014
    [Abstract] [Full Text] [Related]

  • 18. Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.
    Weinreb O, Amit T, Sagi Y, Drigues N, Youdim MB.
    J Neural Transm (Vienna); 2009 Nov 25; 116(11):1457-72. PubMed ID: 19396396
    [Abstract] [Full Text] [Related]

  • 19. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture.
    Goggi J, Theofilopoulos S, Riaz SS, Jauniaux E, Stern GM, Bradford HF.
    Neuroreport; 2000 Dec 18; 11(18):3937-41. PubMed ID: 11192605
    [Abstract] [Full Text] [Related]

  • 20. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage.
    Semkova I, Wolz P, Schilling M, Krieglstein J.
    Eur J Pharmacol; 1996 Nov 07; 315(1):19-30. PubMed ID: 8960860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.